PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month
August 02 2021 - 4:30PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform to provide more effective and safer products, with its
lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to
together as “VAZALORE”), today announced that three stock-keeping
units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug
Administration (“FDA”) approved liquid-filled aspirin capsules,
will be available in nearly 8,000 CVS stores later this month.
CVS, a leading health solutions company, is preparing its retail
space with ‘Coming Soon’ placeholders and shelf trays in many of
its stores. This includes all three SKUs: VAZALORE 81 mg, 12 count;
VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.
“As we continue to execute the launch of VAZALORE, we are
excited that CVS has committed to placing our innovative aspirin
product in its stores nationwide. CVS’s focus on the patient is
well aligned with our mission in providing access to VAZALORE for
millions of patients,” stated Natasha Giordano, Chief Executive
Officer of PLx.
CVS joins Walmart, Walgreens, Rite Aid, and many other retailers
in the nationwide launch of VAZALORE, the first and only
FDA-approved liquid-filled aspirin capsules.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that
provides patients with vascular disease and diabetic patients who
are candidates for aspirin therapy based on physician
recommendation, with fast, reliable and predictable platelet
inhibition as compared to enteric-coated aspirin. It also reduces
the risk of stomach erosions and ulcers, as compared to
immediate-release aspirin, common in an acute setting. To learn
more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on
its clinically-validated and patent-protected PLxGuard™ drug
delivery platform to provide more effective and safer products. The
PLxGuard drug delivery platform works by targeting the release of
active pharmaceutical ingredients to various portions of the
gastrointestinal (GI) tract. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach
erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d8d9940c-c2da-487f-b090-acaada2dbcdc
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024